Amazon jumps 5% after AWS and OpenAI announce $38B partnership
Investing.com - TD Cowen initiated coverage on DiaMedica Therapeutics Inc. (NASDAQ:DMAC) with a Buy rating on Thursday. The stock, currently trading at $6.69 with a market capitalization of approximately $346 million, has gained over 61% in the past six months.
The research firm’s decision is based on interim proof-of-concept data indicating that DM199, DiaMedica’s lead product candidate, does not cross the placenta and functions as a potent vasodilator in preeclampsia cases. According to InvestingPro, DiaMedica maintains a strong financial position with more cash than debt on its balance sheet.
TD Cowen noted early signs that the treatment enhances placental perfusion, addressing a critical need in preeclampsia management.
Key opinion leaders have expressed enthusiasm for DM199’s potential to treat both hypertension and endothelial dysfunction, which could significantly improve maternal-fetal outcomes in preeclampsia cases.
TD Cowen estimates that DiaMedica’s treatment could generate over $1 billion in peak sales if successful in treating early onset preeclampsia alone. Investors should note that DiaMedica is scheduled to report earnings on November 5th. InvestingPro reveals that three analysts have recently revised their earnings upwards for the upcoming period, though the company is not expected to be profitable this year. The comprehensive InvestingPro Research Report offers deeper insights into DiaMedica’s financial health and growth prospects.
In other recent news, DiaMedica Therapeutics reported its earnings for the second quarter of 2025, showing a slight beat on earnings per share (EPS) expectations. The company posted an EPS loss of $0.18, which was marginally better than the anticipated loss of $0.19. However, no revenue figures were disclosed for this period. During the earnings call, the company highlighted its ongoing clinical trials and strategic initiatives as significant areas of focus. Despite the earnings beat, investor sentiment appeared mixed. In related developments, analysts have not provided any recent upgrades or downgrades for DiaMedica Therapeutics. The company’s future plans and trial outcomes continue to be closely monitored by investors and analysts alike.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.